KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pacira BioSciences (PCRX) Other Non-Current Assets: 2010-2018

Historic Other Non-Current Assets for Pacira BioSciences (PCRX) over the last 9 years, with Dec 2018 value amounting to $657,000.

  • Pacira BioSciences' Other Non-Current Assets fell 26.22% to $560,000 in Q1 2019 from the same period last year, while for Mar 2019 it was $560,000, marking a year-over-year decrease of 26.22%. This contributed to the annual value of $657,000 for FY2018, which is 20.36% down from last year.
  • As of FY2018, Pacira BioSciences' Other Non-Current Assets stood at $657,000, which was down 20.36% from $825,000 recorded in FY2017.
  • Over the past 5 years, Pacira BioSciences' Other Non-Current Assets peaked at $2.6 million during FY2014, and registered a low of $406,000 during FY2015.
  • In the last 3 years, Pacira BioSciences' Other Non-Current Assets had a median value of $657,000 in 2018 and averaged $702,000.
  • Its Other Non-Current Assets has fluctuated over the past 5 years, first plummeted by 84.31% in 2015, then soared by 53.69% in 2016.
  • Yearly analysis of 5 years shows Pacira BioSciences' Other Non-Current Assets stood at $2.6 million in 2014, then crashed by 84.31% to $406,000 in 2015, then skyrocketed by 53.69% to $624,000 in 2016, then skyrocketed by 32.21% to $825,000 in 2017, then declined by 20.36% to $657,000 in 2018.